

# Update: Relay Medical Joint Spectroscopic and Biosensor System for Point-of-Care Testing Patent Granted in China

Toronto, Ontario--(Newsfile Corp. - January 7, 2020) - Relay Medical Corp. (CSE: RELA) (OTC: RYMDF) (FSE: EY2) ("**Relay**" or the "**Company**") is pleased to announce an update to September 11th news release regarding the approval for grant of Chinese Patent Application No. 201580025752.6. The company has been informed that the patent has been officially granted by the Chinese patent authority as patent number CN106716137B with an expiry date of May 20, 2035. This new patent continues to expand the broad reach of Relay's intellectual property portfolio for its HemoPalm Analysis Platform in a rapidly advancing market for healthcare technologies.

## About Relay Medical Corp.

Relay Medical is an evolving "Integrated Medtech Accelerator" headquartered in Toronto, Canada, advancing multiple opportunities for commercialization within a resource efficient infrastructure. Relay is also actively dedicated to scouting and reviewing strategic acquisitions complimentary to current infrastructure assets and intends to grow as a leading engine for MedTech innovation in the health technologies marketplace.

Website: [www.relaymedical.com](http://www.relaymedical.com)

### Contact:

W. Clark Kent  
President

Relay Medical Corp.  
Office. 647-872-9982 ext. 2  
TF. 1-844-247-6633 ext. 2  
[investor.relations@relaymedical.com](mailto:investor.relations@relaymedical.com)

Bernhard Langer  
EU Investor Relations  
Office. +49 (0) 177 774 2314  
Email: [blanger@relaymedical.com](mailto:blanger@relaymedical.com)

## Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the commercialization plans for the HemoPalm product described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at [www.sedar.com](http://www.sedar.com)



To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/51226>